Source comparison
Does BPC-157 Help Gut Health Research: Study Design Comparison
The table below compares methodological approaches across published BPC-157 gastrointestinal research, highlighting models, dosing strategies, and primary measured endpoints that define study quality and reproducibility. Ethanol-induced gastric lesions 10 μg/k
This comparison does not assign a generated winner or score.
- The table below compares methodological approaches across published BPC-157 gastrointestinal research, highlighting models, dosing strategies, and primary measured endpoints that define study quality and reproducibility.
- Ethanol-induced gastric lesions
- 10 μg/kg IP daily × 7 days
- Ulcer area, histology, mucus thickness
- 65% reduction in lesion area vs control; increased mucus secretion
- Demonstrates mucosal cytoprotection under acute chemical injury
- TNBS-induced colitis
- 10 μg/kg IP daily × 14 days
- Macroscopic damage score, MPO activity, cytokine levels
- 60% reduction in damage score; 50% reduction in MPO; normalized IL-10/TNF-α ratio
- Regulatory anti-inflammatory effect without immunosuppression
- NSAID enteropathy (indomethacin)
- 10 μg/kg SC + oral gavage daily × 5 days
- Intestinal lesion count, permeability markers
- 70% reduction in lesion incidence; reduced lactulose/mannitol ratio
- Maintains barrier integrity under ongoing NSAID exposure
- Colonic anastomosis healing
- 10 μg/kg IP daily × 7 days post-op
- Bursting pressure, hydroxyproline content, histology
- 45% increase in bursting pressure; accelerated collagen deposition
- Enhances surgical healing and tensile strength
- Fistula model (acetic acid)
- 10 μg/kg IP daily × 21 days
- Fistula closure rate, granulation tissue score
- 80% closure rate vs 20% control; reduced abnormal vascularization
- Promotes organized repair over chronic granulation
- What becomes clear across models is dose consistency—10 μg/kg appears to be the optimal range across injury types, with minimal additional benefit at higher doses and reduced efficacy below 5 μg/kg in most protocols. This suggests a therapeutic window rather than linear dose-response, consistent with receptor-mediated effects that saturate at physiological concentrations.